BioSpace

Just a few days after FDA Commissioner Makary resigned, ally Tracy Beth Høeg is also leaving the agency. Her departure comes amid reports of tension over a commissioner’s voucher for Sanofi's diabetes drug. #FDA #vouchers #biospace https://hubs.li/Q04gRLN50

Novartis is letting go of “a select number” of employees within its biomedical research organization, while Takeda is cutting 4,500 employees in fiscal year 2026. Learn more in our layoff tracker. #layoffs #biopharma #biospace https://hubs.li/Q04gNYTs0 https://hubs.li/Q04gNYTs0

🏅 What an incredible win to get to wrap up the week! The BioSpace Editorial Team has won the National Gold Azbee Award of Excellence for their industry news coverage from the American Society of Business Publication Editors (ASBPE)! The Azbees are widely considered the most prestigious honors in B2B and trade journalism, recognizing outstanding editorial work across the industry. Earning gold at the national level is a true testament to the dedication and talent that drives our editorial team every single day. Congratulations to Jennifer "Jef" Akst, Heather McKenzie and Annalee Armstrong! We couldn't be more proud. 🎉 View all national awards here: https://hubs.li/Q04gPR8P0 #Azbee2026 #AzbeeAwards #ASBPE #EditorialExcellence #BioSpace

California life sciences jobs declined 1.8% last year, according to the new California Life Sciences (CLS) sector report. While National Institutes of Health funding and venture capital investment rose, their growth slowed from the previous year. #jobmarket #biopharma #biospace https://hubs.li/Q04gP1M-0

Last call on this poll, which is about to close. If you haven't participated yet, we'd love to hear from you!

Rina-S is the last candidate standing from Genmab’s $1.8 billion ProfoundBio acquisition two years ago, with the Danish drugmaker ending development of another clinical program stemming from the buyout. #drugdevelopment #pharma #biospace https://hubs.li/Q04gNF-x0

A batch of a chemotherapy product made at a Sun facility with a history of quality and compliance issues is being withdrawn from the U.S. market. #manufacturing #pharma #biospace https://hubs.li/Q04gNGzf0

If Biogen has shown that tau can impact cognition, Denali’s technology—validated with an FDA approval in Hunter syndrome—could ensure the medicine gets where it needs to be for the greatest therapeutic impact, analysts said. #FDA #drugdevelopment #biospace https://hubs.li/Q04gNByX0

Aardvark Therapeutics had previously voluntarily suspended studies of ARD-101—and a related asset called ARD-201—after detecting anomalous echocardiographic readings in healthy volunteers that could indicate reduced heart efficiency. #regulatory #FDA #biospace https://hubs.li/Q04gMLTq0

CREATE Medicines is working on a clinical-stage pipeline for cancer, while its autoimmune programs are still in preclinical testing. #seriesb #preclinical #biospace https://hubs.li/Q04gM-Y20